BACKGROUND: LncRNA PTCSC3 is a tumor suppressor in thyroid cancer, and its role in drug resistance of anaplastic thyroid cancer (ATC) to chemotherapy drug doxorubicin was investigated in this study. METHODS: Expression of RNA and protein was analyzed by qRT-PCR and western blot, respectively. Flow cytometry was used to analyze the expression rate of CD133+ cells. The endogenous expression of related genes was modulated by recombinant plasmids and cell transfection. Combination condition and interaction between PTCSC3 and STAT3 were determined by RIP and RNA pull-down assay, respectively. MTT assay was performed to detect cytotoxicity. Chromatin immunoprecipitation was conducted to identify interactions between STAT3 and DNA promoter of INO80. RESULTS: LncRNA PTCSC3 was low-expressed in ATC tissues and cells. Over-expressed PTCSC3 inhibited the drug resistance of ATC to doxorubicin. PTCSC3 negatively regulated STAT3, and STAT3 promoted expression of INO80. PTCSC3 regulated INO80 through STAT3. PTCSC3 suppressed stem cells properties and drug resistance of ATC to doxorubicin. CONCLUSION: LncRNA PTCSC3 inhibits INO80 expression by negatively regulating STAT3, and thereby attenuating drug resistance of ATC to chemotherapy drug doxorubicin.
BACKGROUND: LncRNA PTCSC3 is a tumor suppressor in thyroid cancer, and its role in drug resistance of anaplastic thyroid cancer (ATC) to chemotherapy drug doxorubicin was investigated in this study. METHODS: Expression of RNA and protein was analyzed by qRT-PCR and western blot, respectively. Flow cytometry was used to analyze the expression rate of CD133+ cells. The endogenous expression of related genes was modulated by recombinant plasmids and cell transfection. Combination condition and interaction between PTCSC3 and STAT3 were determined by RIP and RNA pull-down assay, respectively. MTT assay was performed to detect cytotoxicity. Chromatin immunoprecipitation was conducted to identify interactions between STAT3 and DNA promoter of INO80. RESULTS: LncRNA PTCSC3 was low-expressed in ATC tissues and cells. Over-expressed PTCSC3 inhibited the drug resistance of ATC to doxorubicin. PTCSC3 negatively regulated STAT3, and STAT3 promoted expression of INO80. PTCSC3 regulated INO80 through STAT3. PTCSC3 suppressed stem cells properties and drug resistance of ATC to doxorubicin. CONCLUSION: LncRNA PTCSC3 inhibits INO80 expression by negatively regulating STAT3, and thereby attenuating drug resistance of ATC to chemotherapy drug doxorubicin.
Entities:
Keywords:
ATC; PTCSC3; STAT3; doxorubicin; drug resistance
Authors: Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2015-09 Impact factor: 11.908
Authors: Jaroslaw Jendrzejewski; Andrew Thomas; Sandya Liyanarachchi; Andrew Eiterman; Jerneja Tomsic; Huiling He; Hanna S Radomska; Wei Li; Rebecca Nagy; Krzysztof Sworczak; Albert de la Chapelle Journal: J Clin Endocrinol Metab Date: 2015-08-14 Impact factor: 5.958
Authors: Anastasios Maniakas; Veronique-Isabelle Forest; Yelda Jozaghi; Joe Saliba; Michael P Hier; Alex Mlynarek; Michael Tamilia; Richard J Payne Journal: Thyroid Date: 2014-01-23 Impact factor: 6.568
Authors: Tae-Hyun Kim; Sang Yull Lee; Jee Hyun Rho; Na Young Jeong; Young Hwa Soung; Wol Soon Jo; Do-Young Kang; Sung-Heun Kim; Young Hyun Yoo Journal: Mol Cancer Res Date: 2009-10-13 Impact factor: 5.852
Authors: Jaroslaw Jendrzejewski; Huiling He; Hanna S Radomska; Wei Li; Jerneja Tomsic; Sandya Liyanarachchi; Ramana V Davuluri; Rebecca Nagy; Albert de la Chapelle Journal: Proc Natl Acad Sci U S A Date: 2012-05-14 Impact factor: 11.205